Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including the biologics drug substance facility in Rockville, Maryland and a warehousing center in Frederick, Maryland, for US $122.5 million. The transaction, executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO Service Agreement with MacroGenics.
This acquisition expands Bora Biologics' single-use bioreactor (SUB) drug substance manufacturing capacity to 20,000 liters across two active US sites—Rockville, Maryland and San Diego, California—plus a development facility in Zhubei, Taiwan. The move positions Bora to offer a fully integrated biologics platform from development through commercial supply, addressing growing demand for US-based, inspection-proven manufacturing infrastructure as regulatory and supply chain dynamics evolve.
"This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
With the addition of the Rockville facility, Bora Biologics now supports more than four active commercial programs, with over 120 completed GMP batches supplying markets including the US, EU, Japan, Canada, and the UK. The network has undergone five FDA inspections—including two at Rockville and one PMDA review in 2025—with clean results. The platform has supported more than 33 biologics and 15 biosimilars, providing a manufacturing base that reduces offshore dependency.
Bora Group plans to integrate its US drug substance capabilities with existing sterile drug product capabilities over the next 12 to 18 months, aiming to offer a seamless development-through-commercial biologics solution. This integration is expected to enhance value for biotech and pharmaceutical partners seeking a reliable, domestically anchored manufacturing partner. For more information, visit Bora Pharmaceuticals and Bora CDMO.
